Tiamulin is a pleuromutilin antibiotic drug, which is derived semi-synthetically from natural compound— pleuromutilin—originally produced by the mushroom–clitopilus scyphoides. Tiamulin is primarily used as veterinary medicine for treatment of pneumonia, prophylaxis of dysentery, and mycoplasmal infections in pigs and poultry. It acts by inhibiting protein synthesis at ribosomal level and is present in powder and injectable formulations. Antibiotic properties of Tiamulin aid in treatment of wide range of diseases caused by bacteria.
Tiamulin Market: Drivers
Tiamulin aids in treatment and prophylaxis of several diseases such as dysentery, pneumonia, and mycoplasmal infections in pigs and poultry. Increasing demand for pork and poultry meat along with increase in pig farming and poultry is expected to propel demand for antibiotic drug tiamulin and fuel global tiamulin market growth. This is owing to the susceptibility of pigs and poultry animals to various types of infections and diseases. According to a report by National Pork Board, China was the largest pork-producing country in the world. The country produced around 52,990 thousand metric tons of pork in 2016, which was increased to 53,400 thousand metric tons in 2017.
According to a report by Federal Statistical Office in 2014, the U.S. was the largest producer of poultry meat with around 18% of the total meat produced worldwide. High production of poultry meat is expected to increase demand for Tiamulin antibiotic drug to treat poultry animals from various infections. This in turn is expected to propel growth of the Tiamulin market in the region over the forecast period.
Furthermore, initiatives by various private and government organizations for spreading awareness for use of antibiotics in pig farms is expected to propel global tiamulin market growth over forecast period. For instance, in 2017, National Pork Board celebrated The U.S. Antibiotic Awareness Week and World Antibiotic Awareness Week with organizations such as the U.S. Centers for Disease Control and Prevention (CDC) for spreading awareness for use of antibiotic drugs in pigs.
Tiamulin Market: Regional Analysis
North America is expected to hold a dominant position in the global Tiamulin market over the forecast period, owing to the presence of key players in the region along with several strategic mergers and acquisitions amongst the key players. For instance, in 2015, US-based Eli Lilly and Company acquired Novartis Animal Health Inc. and its product –Denagard (tiamulin hydrogen fumarate) and strengthen the position of Eli Lilly and Company’s animal health business arm Elanco US, Inc.
Asia Pacific tiamulin market is expected to witness significant growth over forecast period, owing to increase in the number of pig farms in the region. For instance, according to report by Federal Statistical Office in 2014, China was the largest producer of pork with around 48% of the total pork produced worldwide. Such increasing production of pork is expected to propel the demand for antibiotics such as Tiamulin for the treatment of pigs.
Furthermore, Europe tiamulin market is expected to witness significant growth over the forecast period, owing to high rates of pork production, which is expected to increase demand for antibiotic drugs, such as Tiamulin. For instance, according to a report by National Pork Board, Europe is the second largest producer of pork worldwide with around 23,866 thousand metric tons pork produced in 2016 and 23,675 thousand metric tons pork produced in 2017.
Tiamulin Market: Restraint
Use of Tiamulin results in some side effects, which is expected to be a major factor hindering growth of the Tiamulin market over the forecast period. Tiamulin injection can cause pain in the animals and long-term treatment with Tiamulin results in its resistance in bacteria.
Furthermore, stringent regulation by U.S. Food and Drug Administration for sale of Tiamulin drugs is also expected to adversely affect the tiamulin market growth. For instance, in 2013, U.S. Food and Drug Administration drafted new guidelines to ban the sale of any medically use antibiotics for non-medical applications. In 2014, Novartis Animal Health Inc. (now a part of Eli Lilly and Company) received warning form FDA, as it promoted its swine antibiotic product— Denagard (tiamulin hydrogen fumarate) for growth-promotion aspects.
Tiamulin Market: Key Players
Key players operating in the global Tiamulin market include Elanco Inc., Hester Biosciences Limited, Huvepharma AD, Jiangsu SEL Biochem, Shandong Shengli Co Ltd, and others.
Tiamulin Market: Taxonomy
The global Tiamulin Market is segmented on the basis of dosage from, target animal, distribution channel, and region
By Dosage From
By Target Animal
By Distribution Channel
- Veterinary Hospital
- Retail Pharmacies
- Online Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East